Usman Sheriff, MD
Cardiovascular Disease · Harlingen, TXNPI 1356396303
Payments from drug & device makers
What this record shows
This record is dominated by other: $34,667 of the $44,689 with a category attached, or 77.6%. Angiodynamics, Inc. accounts for 77.7% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $30,244, more than ten times the $2,966 reported in 2019. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $249.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$35K
- Surmodics, Inc.$2K
- Bard Peripheral Vascular, Inc.$2K
- Penumbra, Inc.$2K
- Medtronic$716
- Philips North America LLC$673
- plus $3K from 17 others
What the payments were for
- Travel & lodging$5,85213%
- Food & beverage$4,0719%
- Education$990%
- Other$34,66778%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $34,723 |
| Surmodics, Inc. | 12 | $2,180 |
| Bard Peripheral Vascular, Inc. | 33 | $1,966 |
| Penumbra, Inc. | 6 | $1,534 |
| Medtronic(2 entities) | 17 | $716 |
| Philips North America LLC | 1 | $673 |
| Abiomed | 3 | $650 |
| Endologix LLC | 4 | $512 |
| E.r. Squibb & Sons, L.L.C. | 31 | $442 |
| Pfizer | 22 | $420 |
| Amgen | 19 | $327 |
| AstraZeneca | 6 | $165 |
| Novartis | 7 | $124 |
| Johnson & Johnson | 5 | $86 |
| Edwards Lifesciences | 1 | $36 |
| Abbott | 1 | $25 |
| Merck | 1 | $23 |
| Boehringer Ingelheim | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Biotronik Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$34,667
- Sublime 014 Rx PTA Balloon Dilatation Catheter$3,751
- Sublime Radial Access 018 RX PTA Dilatation Catheter$1,876
- Sublime Microcatheter, 014, 65cm, Straight$1,876
- Sublime Microcatheter, 014, 65cm, Angle$1,876
- Indigo System$1,410
- VENOVO$892
- IGT D Peripheral$673
- Impella$604
- VenaSeal$444
- Torus Stent Graft System$382
- Venclose Maven Catheter$242
- Pounce Thrombectomy System$169
- Pounce Venous Thrombectomy System$169
- Pounce Thrombectomy$169
- LUTONIX$162
- ENDOCROSS Device$138
How this compares
$44,689 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 460 | $383,074 |
| EntrestoSacubitril/Valsartan | 60 | $60,100 |
| FarxigaDapagliflozin Propanediol | 56 | $53,240 |
| XareltoRivaroxaban | 48 | $38,976 |
| Repatha SyringeEvolocumab | 12 | $16,957 |
| BrilintaTicagrelor | 20 | $15,246 |
| ClopidogrelClopidogrel Bisulfate | 641 | $4,068 |
| Carvedilol | 526 | $3,296 |
| Metoprolol Succinate | 294 | $3,024 |
| Midodrine Hcl | 27 | $2,846 |
| Metoprolol Tartrate | 514 | $2,832 |
| Losartan Potassium | 349 | $2,464 |
| Ezetimibe | 92 | $2,256 |
| Rosuvastatin Calcium | 225 | $2,203 |
| Amiodarone Hcl | 113 | $1,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $420 | $383,074460 claims |
| AstraZenecaFarxiga, Brilinta | $165 | $68,48676 claims |
| NovartisEntresto | $124 | $60,10060 claims |
| Johnson & JohnsonXarelto | $86 | $38,97648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Harlingen
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.